Homology Medicines

company

About

Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.

  • 101 - 250

Details

Last Funding Type
Series A
Last Funding Money Raised
$43.50M
Industries
Alternative Medicine,Biotechnology,Genetics,Health Care
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$127M
Homology Medicines has raised a total of $127M in funding over 2 rounds. Their latest funding was raised on Aug 1, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 1, 2017 Series B $83.50M 1 Detail
May 2, 2016 Series A $43.50M 2 ARCH Venture Partners Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Homology Medicines is funded by 2 investors. ARCH Venture Partners and ARCH Overage Fund are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B
ARCH Overage Fund Series A